Objective: To test the hypothesis that cognitively unimpaired individuals with Alzheimer disease (AD) neuropathology differ from individuals with AD dementia on biomarkers of neurodegeneration, synaptic dysfunction, and glial activation. Methods: In a cross-sectional study, adult participants >70 years old (n = 79, age 77.1 ± 5.3 years) underwent comprehensive cognitive evaluation and CSF collection, which was assayed for markers of amyloid, phosphorylated tau (p-tau), neurodegeneration (neurofilament light protein [NFL] and total tau), synaptic dysfunction (neurogranin), and glial activation (chitinase-3–like protein 1 [YKL-40]). Participants were divided into 3 groups based on diagnosis and p-tau/β-amyloid42 (Aβ42): those with low p-ta...
OBJECTIVES: This longitudinal study compared emerging plasma biomarkers for neurodegenerative diseas...
Introduction: We investigated relations between amyloid-beta (A beta) status, apolipoprotein E (APOE...
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by tau and amyloi...
Introduction: We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, a...
INTRODUCTION: This study examines the utility of a multipanel of cerebrospinal fluid (CSF) biomarker...
Introduction: We examined the ability of plasma hyperphosphorylated tau (p-tau)181 to detect cognit...
Introduction We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, an...
ImportanceCriteria for preclinical Alzheimer disease (AD) propose β-amyloid (Aβ) plaques to initiate...
OBJECTIVE: To examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cor...
Currently, approximately 50 million individuals have dementia, and this number is expected to rise d...
Objective: To investigate the relationship between Alzheimer's disease biomarkers and neuropsychiatr...
Introduction: We investigated relations between amyloid-beta (A beta) status, apolipoprotein E (APOE...
OBJECTIVE: Plasma p-tau181, a well-validated marker of Alzheimer's disease (AD) pathological change,...
Introduction: The biological pathways involved in the preclinical stage of the Alzheimer's continuum...
ObjectiveTo examine whether the association between clinical Alzheimer disease (AD) diagnosis and ne...
OBJECTIVES: This longitudinal study compared emerging plasma biomarkers for neurodegenerative diseas...
Introduction: We investigated relations between amyloid-beta (A beta) status, apolipoprotein E (APOE...
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by tau and amyloi...
Introduction: We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, a...
INTRODUCTION: This study examines the utility of a multipanel of cerebrospinal fluid (CSF) biomarker...
Introduction: We examined the ability of plasma hyperphosphorylated tau (p-tau)181 to detect cognit...
Introduction We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, an...
ImportanceCriteria for preclinical Alzheimer disease (AD) propose β-amyloid (Aβ) plaques to initiate...
OBJECTIVE: To examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cor...
Currently, approximately 50 million individuals have dementia, and this number is expected to rise d...
Objective: To investigate the relationship between Alzheimer's disease biomarkers and neuropsychiatr...
Introduction: We investigated relations between amyloid-beta (A beta) status, apolipoprotein E (APOE...
OBJECTIVE: Plasma p-tau181, a well-validated marker of Alzheimer's disease (AD) pathological change,...
Introduction: The biological pathways involved in the preclinical stage of the Alzheimer's continuum...
ObjectiveTo examine whether the association between clinical Alzheimer disease (AD) diagnosis and ne...
OBJECTIVES: This longitudinal study compared emerging plasma biomarkers for neurodegenerative diseas...
Introduction: We investigated relations between amyloid-beta (A beta) status, apolipoprotein E (APOE...
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by tau and amyloi...